180 related articles for article (PubMed ID: 22474725)
21. The early repigmentation pattern of vitiligo is related to the source of melanocytes and by the choice of therapy: a retrospective cohort study.
Yang K; Xiong X; Pallavi G; Ling Y; Ding F; Duan W; Sun W; Ding G; Gong Q; Zhu W; Lu Y
Int J Dermatol; 2018 Mar; 57(3):324-331. PubMed ID: 29318595
[TBL] [Abstract][Full Text] [Related]
22. Clinical and epidemiological analysis in 149 cases of rhododendrol-induced leukoderma.
Yoshikawa M; Sumikawa Y; Hida T; Kamiya T; Kase K; Ishii-Osai Y; Kato J; Kan Y; Kamiya S; Sato Y; Yamashita T
J Dermatol; 2017 May; 44(5):582-587. PubMed ID: 27882588
[TBL] [Abstract][Full Text] [Related]
23. Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature.
Mosher DB; Parrish JA; Fitzpatrick TB
Br J Dermatol; 1977 Dec; 97(6):669-79. PubMed ID: 603749
[TBL] [Abstract][Full Text] [Related]
24. Mutant HSP70 reverses autoimmune depigmentation in vitiligo.
Mosenson JA; Zloza A; Nieland JD; Garrett-Mayer E; Eby JM; Huelsmann EJ; Kumar P; Denman CJ; Lacek AT; Kohlhapp FJ; Alamiri A; Hughes T; Bines SD; Kaufman HL; Overbeck A; Mehrotra S; Hernandez C; Nishimura MI; Guevara-Patino JA; Le Poole IC
Sci Transl Med; 2013 Feb; 5(174):174ra28. PubMed ID: 23447019
[TBL] [Abstract][Full Text] [Related]
25. Depigmentation of black guinea pig skin by topical application of cysteaminylphenol, cysteinylphenol, and related compounds.
Ito Y; Jimbow K; Ito S
J Invest Dermatol; 1987 Jan; 88(1):77-82. PubMed ID: 3794391
[TBL] [Abstract][Full Text] [Related]
26. Vitiligo: an update on current pharmacotherapy and future directions.
Colucci R; Lotti T; Moretti S
Expert Opin Pharmacother; 2012 Sep; 13(13):1885-99. PubMed ID: 22835073
[TBL] [Abstract][Full Text] [Related]
27. Management of vitiligo patients with surgical interventions.
Shokeen D
Cutis; 2016 May; 97(5):E27-9. PubMed ID: 27274556
[TBL] [Abstract][Full Text] [Related]
28. Depigmentation of the normally pigmented patches in universal vitiligo patients by cryotherapy.
Radmanesh M
J Eur Acad Dermatol Venereol; 2000 May; 14(3):149-52. PubMed ID: 11032055
[TBL] [Abstract][Full Text] [Related]
29. The in vivo melanocytotoxicity and depigmenting potency of N-2,4-acetoxyphenyl thioethyl acetamide in the skin and hair.
Jimbow M; Marusyk H; Jimbow K
Br J Dermatol; 1995 Oct; 133(4):526-36. PubMed ID: 7577578
[TBL] [Abstract][Full Text] [Related]
30. Site-oriented depigmentation in vitiligo patients using Q-switched Nd:YAG laser (1,064/532 nm), cryotherapy and chemical peels: A comparative study.
El-Mofty M; Mostafa WZ; Esmat S; Zayed A; Mashaly H; Hussien MF; Ismail SI
Dermatol Ther; 2019 Sep; 32(5):e13052. PubMed ID: 31376312
[TBL] [Abstract][Full Text] [Related]
31. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial.
Szczurko O; Shear N; Taddio A; Boon H
BMC Complement Altern Med; 2011 Mar; 11():21. PubMed ID: 21406109
[TBL] [Abstract][Full Text] [Related]
32. Psychosocial and quality-of-life factors associated with depigmentation therapy for vitiligo.
Cadmus SD; Riddle AO; Sebastian KR; Reddy PS; Ahmed AM
Arch Dermatol Res; 2023 Oct; 315(8):2283-2288. PubMed ID: 36964766
[TBL] [Abstract][Full Text] [Related]
33. Combined therapy for resistant vitiligo lesions: NB-UVB, microneedling, and topical latanoprost, showed no enhanced efficacy compared to topical latanoprost and NB-UVB.
Stanimirovic A; Kovacevic M; Korobko I; Šitum M; Lotti T
Dermatol Ther; 2016 Sep; 29(5):312-316. PubMed ID: 27356486
[TBL] [Abstract][Full Text] [Related]
34. Q-switched laser therapy for recalcitrant and recurrent pigmentation after chemical depigmentation for extensive vitiligo.
Durham AB; Orringer JS
Dermatol Surg; 2012 Sep; 38(9):1563-5. PubMed ID: 22620980
[No Abstract] [Full Text] [Related]
35. Vitiligo road map.
Lee BW; Schwartz RA; Hercogová J; Valle Y; Lotti TM
Dermatol Ther; 2012; 25 Suppl 1():S44-56. PubMed ID: 23237038
[TBL] [Abstract][Full Text] [Related]
36. Autoimmune response against tyrosinase induces depigmentation in C57BL/6 black mice.
Al Robaee AA; Alzolibani AA; Rasheed Z
Autoimmunity; 2020 Dec; 53(8):459-466. PubMed ID: 33084421
[TBL] [Abstract][Full Text] [Related]
37. In vivo evaluation of piperine and synthetic analogues as potential treatments for vitiligo using a sparsely pigmented mouse model.
Faas L; Venkatasamy R; Hider RC; Young AR; Soumyanath A
Br J Dermatol; 2008 May; 158(5):941-50. PubMed ID: 18284389
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic update on vitiligo.
Sarnoff DS
J Drugs Dermatol; 2015 Feb; 14(2):109-11. PubMed ID: 25689803
[No Abstract] [Full Text] [Related]
39. Rapid repigmentation after depigmentation therapy: vitiligo treated with monobenzyl ether of hydroquinone.
Oakley AM
Australas J Dermatol; 1996 May; 37(2):96-8. PubMed ID: 8687336
[TBL] [Abstract][Full Text] [Related]
40. Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo.
Goldinger SM; Dummer R; Schmid P; Burg G; Seifert B; Läuchli S
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):504-8. PubMed ID: 17373978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
